The Past, Present, and Future of mRNA Vaccines

Guest Editor:

Prof. Dr. Norbert Pardi
Department of Medicine,
University of Pennsylvania,
Philadelphia, PA, USA
pnorbert@
pennmedicine.upenn.edu

Deadline for manuscript submissions:
closed (1 January 2021)

Message from the Guest Editor

Vaccines represent one of the most successful interventions of modern medicine. Currently used vaccine types have many shortfalls, and, thus, the development of next-generation vaccines that are safe, easy-to-produce, and offer broad and durable protection against a wide range of pathogens and have the ability to eliminate various types of cancer is urgently needed. mRNA vaccines have the potential to meet these criteria and, thus, represent one of the most promising new generation vaccine modalities.

This Special Issue of Vaccines will provide a series of peer-reviewed perspective and review articles that discuss the current standing and speculate on the future of the field of mRNA vaccines. This Special Issue will discuss a broad range of topics including recent developments in various types of infectious disease and cancer mRNA vaccines, passive immunization with mRNA, delivery materials, and production of mRNA vaccines, among other topics.
**Editor-in-Chief**

**Prof. Dr. Ralph A. Tripp**  
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia  
Athens, GA 30602-7387, USA

---

**Message from the Editor-in-Chief**

_Vaccines_ (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

**Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.  

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and many other databases.  

**Journal Rank:** JCR - Q2 (Immunology)

---

**Contact Us**

_Vaccines_  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
www.mdpi.com  
mdpi.com/journal/vaccines  
vaccines@mdpi.com